News and Events

News

All categories

Earnings

Press Release

All years

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress

November 14, 2023

Affimed Announces Acimtamig as International Nonproprietary Name for AFM13

November 9, 2023

Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023

November 7, 2023

Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

November 3, 2023

Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting

November 2, 2023

Affimed to Participate in Upcoming Investor Conferences

November 1, 2023

Affimed Announces Listing Transfer to Nasdaq Capital Markets

October 4, 2023

Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

September 27, 2023

Affimed to Present at the Cantor Global Healthcare Conference 2023

September 21, 2023

Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK^® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma

September 12, 2023

Events

All

Scientific

Investors

09Dec

ASH Annual Meeting

December 9 - 12, 2023 (San Diego, USA)

Webcasts More events

News and Events

News and Events

See what’s new at Affimed

See what’s new at Affimed

News

Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress

Affimed Announces Acimtamig as International Nonproprietary Name for AFM13

Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023

Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting

Affimed to Participate in Upcoming Investor Conferences

Affimed Announces Listing Transfer to Nasdaq Capital Markets

Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

Affimed to Present at the Cantor Global Healthcare Conference 2023

Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK^® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma

Events

ASH Annual Meeting